{
  "symbol": "MRK",
  "year": 2024,
  "Period": "Q2",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.2465,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.07
  },
  "top_positive": [
    {
      "sent": "Unregistered Sales of Equity Securities and Use of Proceeds Issuer purchases of equity securities for the three months ended June\u00a030, 2024 were as follows: ISSUER PURCHASES OF EQUITY SECURITIES ($\u00a0in\u00a0millions) Period Total\u00a0Number of Shares Purchased (1) Average\u00a0Price Paid Per Share Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs Approximate\u00a0Dollar\u00a0Value\u00a0of\u00a0Shares That May Yet Be Purchased Under the Plans or Programs (1) April 1 - April 30 408,640 $126.80 408,640 $3,527 May 1 - May 31 811,903 $129.33 811,903 $3,422 June 1 - June 30 727,448 $129.80 727,448 $3,328 Total 1,947,991 $128.97 1,947,991 (1) Shares purchased during the period were made as part of a plan approved by the Board of Directors in October 2018 to purchase up to $10 billion of Merck\u2019s common stock for its treasury.",
      "score": 0.968
    },
    {
      "sent": "Restructuring In January 2024, the Company approved a new restructuring program (2024 Restructuring Program) intended to continue the optimization of the Company\u2019s Human Health global manufacturing network as the future pipeline shifts to new modalities and also optimize the Animal Health global manufacturing network to improve supply reliability and increase efficiency.",
      "score": 0.936
    },
    {
      "sent": "Restructuring Costs In January 2024, the Company approved a new restructuring program (2024 Restructuring Program) intended to continue the optimization of the Company\u2019s Human Health global manufacturing network as the future pipeline shifts to new - 37 - modalities and also optimize the Animal Health global manufacturing network to improve supply reliability and increase efficiency.",
      "score": 0.936
    }
  ],
  "top_negative": [
    {
      "sent": "Phase 2 Cancer MK-1022 (patritumab deruxtecan) (1) Gastric Head and Neck Melanoma MK-1308 (quavonlimab) (2) Non-Small-Cell Lung MK-1308A (quavonlimab+pembrolizumab) Colorectal MK-2140 (zilovertamab vedotin) Hematological Malignancies MK-2400 (ifinatamab deruxtecan) (1) Bladder Colorectal Endometrial Head and Neck MK-2870 (sacituzumab tirumotecan) (1)(3) Biliary Colorectal Neoplasm Malignant Pancreatic MK-3475 Keytruda Advanced Solid Tumors Prostate MK-3475A (pembrolizumab+hyaluronidase subcutaneous) Cutaneous Squamous Cell MK-4280 (favezelimab) (2) Non-Small-Cell Lung MK-4280A (favezelimab+pembrolizumab) Bladder Cutaneous Squamous Cell Endometrial Esophageal Melanoma Renal Cell MK-5890 (boserolimab) (2) Neoplasm Malignant Cancer MK-5909 (raludotatug deruxtecan) (1) Ovarian MK-6482 Welireg (3) Endometrial Esophageal Hepatocellular Prostate Rare cancers MK-7339 Lynparza (1)(3) Advanced Solid Tumors MK-7684A (vibostolimab+pembrolizumab) Bladder Colorectal Endometrial Melanoma Ovarian Prostate Renal Cell MK-7902 Lenvima (1)(2) Head and Neck V940 (1)(2) Cutaneous Squamous Cell Bladder Renal Cell Dengue Fever Virus Vaccine V181 Diabetic Macular Edema MK-3000 Restoret HIV-1 Infection MK-8591B (islatravir+MK-8507) (4) MK-8591D (islatravir+lenacapavir) (1)(5) HIV-1 Prevention MK-8527 Nonalcoholic Steatohepatitis (NASH) MK-6024 (efinopegdutide) Pulmonary Hypertension-Chronic Obstructive Pulmonary Disease MK-5475 Pulmonary Hypertension Due To Left Heart Disease MK-7962 Winrevair Schizophrenia MK-8189 (6) Thrombosis MK-2060 Vitiligo MK-6194 - 42 - Phase 3 (Phase 3 entry date) Under Review Antiviral COVID-19 MK-4482 Lagevrio (U.S.) (May 2021) (1)(7) Cancer MK-1022 (patritumab deruxtecan) (1) Non-Small-Cell Lung (May 2022) (EU) MK-1026 (nemtabrutinib) Hematological Malignancies (March 2023) MK-1084 Non-Small-Cell Lung (May 2024) MK-1308A (quavonlimab+pembrolizumab) Renal Cell (April 2021) MK-2400 (ifinatamab deruxtecan) (1) Small-Cell Lung (July 2024) MK-2870 (sacituzumab tirumotecan) (1)(3) Breast (April 2024) Cervical (July 2024) Gastric (May 2024) Endometrial (December 2023) Non-Small-Cell Lung (November 2023) MK-3475 Keytruda Cutaneous Squamous Cell (August 2019) (EU) Hepatocellular (May 2016) (EU) Ovarian (December 2018) Small-Cell Lung (May 2017) MK-3475A (pembrolizumab+hyaluronidase subcutaneous) Non-Small-Cell Lung (February 2023) MK-3543 (bomedemstat) Myeloproliferative Disorders (December 2023) MK-4280A (favezelimab+pembrolizumab) Colorectal (November 2021) Hematological Malignancies (October 2022) MK-5684 (opevesostat) (1) Prostate (December 2023) MK-7339 Lynparza (1)(2) Non-Small-Cell Lung (June 2019) Small-Cell Lung (December 2020) MK-7684A (vibostolimab+pembrolizumab) Non-Small-Cell Lung (April 2021) Small-Cell Lung (March 2022) MK-7902 Lenvima (1)(2) Esophageal (July 2021) Gastric (December 2020) V940 (1)(2) Melanoma (July 2023) Non-Small-Cell Lung (December 2023) HIV-1 Infection MK-8591A (doravirine+islatravir) (February 2020) (5) Hypercholesterolemia MK-0616 (August 2023) Respiratory Syncytial Virus MK-1654 (clesrovimab) (November 2021) Ulcerative Colitis MK-7240 (tulisokibart) (October 2023) New Molecular Entities Ca ncer MK-1022 (patritumab deruxtecan) (1)(8) Non-Small-Cell Lung (U.S.) MK-6482 Welireg Von Hippel-Lindau (VHL) Disease (EU) Cough MK-7264 (gefapixant) (U.S.) (9) Pneumococcal Vaccine Adult V116 Capvaxive (EU) Pulmonary Arterial Hypertension MK-7962 Winrevair (EU) Certain Supplemental Filings Cancer MK-3475 Keytruda \u2022    First-Line Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (KEYNOTE-483) (U.S.) (EU) (JPN) \u2022    Primary Advanced or Recurrent Endometrial Carcinoma (KEYNOTE-868) (EU) (JPN) \u2022    First-Line Locally Advanced or Metastatic Urothelial Carcinoma (KEYNOTE-A39) (EU) (JPN) \u2022    High-Risk Locally Advanced Cervical Cancer (KEYNOTE-A18) (EU) (JPN) \u2022    Resectable Stage II, IIIA or IIIB (T3-4N2) NSCLC (KEYNOTE-671) (JPN) MK-6482 Welireg \u2022    Previously Treated Advanced Renal Cell Carcinoma (LITESPARK-005) (EU) (JPN) Footnotes: (1) Being developed in a collaboration.",
      "score": -0.8934
    },
    {
      "sent": "The change was primarily due to lower proceeds from the - 43 - issuance of debt, no proceeds from short-term borrowings and higher dividends paid to shareholders, partially offset by lower payments on long-term debt, lower purchases of treasury stock and higher p\nItem 7A.",
      "score": -0.875
    },
    {
      "sent": "\u2014 1,192 Deferred income taxes ( 232 ) ( 632 ) Share-based compensation 379 314 Other 174 5 Net changes in assets and liabilities ( 4,394 ) ( 4,526 ) Net Cash Provided by Operating Activities 8,727 5,043 Cash Flows from Investing Activities Capital expenditures ( 1,652 ) ( 1,972 ) Purchases of securities and other investments ( 64 ) ( 587 ) Proceeds from sales of securities and other investments 320 785 Acquisition of Harpoon Therapeutics, Inc., net of cash acquired ( 746 ) \u2014 Acquisition of Prometheus Biosciences, Inc., net of cash acquired \u2014 ( 10,705 ) Acquisition of Imago BioSciences, Inc., net of cash acquired \u2014 ( 1,327 ) Other ( 303 ) 4 Net Cash Used in Investing Activities ( 2,445 ) ( 13,802 ) Cash Flows from Financing Activities Net change in short-term borrowings \u2014 1,937 Proceeds from issuance of debt 3,600 5,946 Payments on debt ( 751 ) ( 1,751 ) Dividends paid to stockholders ( 3,936 ) ( 3,738 ) Purchases of treasury stock ( 373 ) ( 487 ) Proceeds from exercise of stock options 160 112 Other ( 298 ) ( 315 ) Net Cash (Used in) Provided by Financing Activities ( 1,598 ) 1,704 Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash ( 220 ) ( 6 ) Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash 4,464 ( 7,061 ) Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $ 68 and $ 79 at January 1, 2024 and 2023, respectively, included in Other current assets ) 6,909 12,773 Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $ 69 and $ 52 at June\u00a030, 2024 and 2023, respectively, included in Other current assets ) $ 11,373 $ 5,712 The accompanying notes are an integral part of this condensed consolidated financial statement.",
      "score": -0.7184
    }
  ],
  "forward_snippets": [
    "Recently Adopted Accounting Standard In August 2023, the Financial Accounting Standards Board (FASB) issued amended guidance that requires a newly formed joint venture to recognize and initially measure its assets and liabilities at fair value upon formation.",
    "The amended guidance includes exceptions to fair value measurement that are consistent with the accounting for \nenerally accepted in the United States (U.S.) for complete consolidated financial statements are not included herein.",
    "Recently Adopted Accounting Standard In August 2023, the Financial Accounting Standards Board (FASB) issued amended guidance that requires a newly formed joint venture to recognize and initially measure its assets and liabilities at fair value upon formation.",
    "The amended guidance includes exceptions to fair value measurement that are consistent with the accounting for business combinations guidance.",
    "The amended guidance is effective prospectively for all joint ventures with a formation date on or after January 1, 2025, however existing joint ventures have the option to apply the guidance retrospectively."
  ],
  "curated_text": "Symbol: MRK. Year: 2024. Period: Q2. ReportType: Q10. Section: Management Discussion and Analysis (MD&A). Key metrics include sentiment, forward outlook, and risk hedging.  Top positive sentences: Unregistered Sales of Equity Securities and Use of Proceeds Issuer purchases of equity securities for the three months ended June\u00a030, 2024 were as follows: ISSUER PURCHASES OF EQUITY SECURITIES ($\u00a0in\u00a0millions) Period Total\u00a0Number of Shares Purchased (1) Average\u00a0Price Paid Per Share Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs Approximate\u00a0Dollar\u00a0Value\u00a0of\u00a0Shares That May Yet Be Purchased Under the Plans or Programs (1) April 1 - April 30 408,640 $126.80 408,640 $3,527 May 1 - May 31 811,903 $129.33 811,903 $3,422 June 1 - June 30 727,448 $129.80 727,448 $3,328 Total 1,947,991 $128.97 1,947,991 (1) Shares purchased during the period were made as part of a plan approved by the Board of Directors in October 2018 to purchase up to $10 billion of Merck\u2019s common stock for its treasury. Restructuring In January 2024, the Company approved a new restructuring program (2024 Restructuring Program) intended to continue the optimization of the Company\u2019s Human Health global manufacturing network as the future pipeline shifts to new modalities and also optimize the Animal Health global manufacturing network to improve supply reliability and increase efficiency. Restructuring Costs In January 2024, the Company approved a new restructuring program (2024 Restructuring Program) intended to continue the optimization of the Company\u2019s Human Health global manufacturing network as the future pipeline shifts to new - 37 - modalities and also optimize the Animal Health global manufacturing network to improve supply reliability and increase efficiency. Top negative sentences: Phase 2 Cancer MK-1022 (patritumab deruxtecan) (1) Gastric Head and Neck Melanoma MK-1308 (quavonlimab) (2) Non-Small-Cell Lung MK-1308A (quavonlimab+pembrolizumab) Colorectal MK-2140 (zilovertamab vedotin) Hematological Malignancies MK-2400 (ifinatamab deruxtecan) (1) Bladder Colorectal Endometrial Head and Neck MK-2870 (sacituzumab tirumotecan) (1)(3) Biliary Colorectal Neoplasm Malignant Pancreatic MK-3475 Keytruda Advanced Solid Tumors Prostate MK-3475A (pembrolizumab+hyaluronidase subcutaneous) Cutaneous Squamous Cell MK-4280 (favezelimab) (2) Non-Small-Cell Lung MK-4280A (favezelimab+pembrolizumab) Bladder Cutaneous Squamous Cell Endometrial Esophageal Melanoma Renal Cell MK-5890 (boserolimab) (2) Neoplasm Malignant Cancer MK-5909 (raludotatug deruxtecan) (1) Ovarian MK-6482 Welireg (3) Endometrial Esophageal Hepatocellular Prostate Rare cancers MK-7339 Lynparza (1)(3) Advanced Solid Tumors MK-7684A (vibostolimab+pembrolizumab) Bladder Colorectal Endometrial Melanoma Ovarian Prostate Renal Cell MK-7902 Lenvima (1)(2) Head and Neck V940 (1)(2) Cutaneous Squamous Cell Bladder Renal Cell Dengue Fever Virus Vaccine V181 Diabetic Macular Edema MK-3000 Restoret HIV-1 Infection MK-8591B (islatravir+MK-8507) (4) MK-8591D (islatravir+lenacapavir) (1)(5) HIV-1 Prevention MK-8527 Nonalcoholic Steatohepatitis (NASH) MK-6024 (efinopegdutide) Pulmonary Hypertension-Chronic Obstructive Pulmonary Disease MK-5475 Pulmonary Hypertension Due To Left Heart Disease MK-7962 Winrevair Schizophrenia MK-8189 (6) Thrombosis MK-2060 Vitiligo MK-6194 - 42 - Phase 3 (Phase 3 entry date) Under Review Antiviral COVID-19 MK-4482 Lagevrio (U.S.) (May 2021) (1)(7) Cancer MK-1022 (patritumab deruxtecan) (1) Non-Small-Cell Lung (May 2022) (EU) MK-1026 (nemtabrutinib) Hematological Malignancies (March 2023) MK-1084 Non-Small-Cell Lung (May 2024) MK-1308A (quavonlimab+pembrolizumab) Renal Cell (April 2021) MK-2400 (ifinatamab deruxtecan) (1) Small-Cell Lung (July 2024) MK-2870 (sacituzumab tirumotecan) (1)(3) Breast (April 2024) Cervical (July 2024) Gastric (May 2024) Endometrial (December 2023) Non-Small-Cell Lung (November 2023) MK-3475 Keytruda Cutaneous Squamous Cell (August 2019) (EU) Hepatocellular (May 2016) (EU) Ovarian (December 2018) Small-Cell Lung (May 2017) MK-3475A (pembrolizumab+hyaluronidase subcutaneous) Non-Small-Cell Lung (February 2023) MK-3543 (bomedemstat) Myeloproliferative Disorders (December 2023) MK-4280A (favezelimab+pembrolizumab) Colorectal (November 2021) Hematological Malignancies (October 2022) MK-5684 (opevesostat) (1) Prostate (December 2023) MK-7339 Lynparza (1)(2) Non-Small-Cell Lung (June 2019) Small-Cell Lung (December 2020) MK-7684A (vibostolimab+pembrolizumab) Non-Small-Cell Lung (April 2021) Small-Cell Lung (March 2022) MK-7902 Lenvima (1)(2) Esophageal (July 2021) Gastric (December 2020) V940 (1)(2) Melanoma (July 2023) Non-Small-Cell Lung (December 2023) HIV-1 Infection MK-8591A (doravirine+islatravir) (February 2020) (5) Hypercholesterolemia MK-0616 (August 2023) Respiratory Syncytial Virus MK-1654 (clesrovimab) (November 2021) Ulcerative Colitis MK-7240 (tulisokibart) (October 2023) New Molecular Entities Ca ncer MK-1022 (patritumab deruxtecan) (1)(8) Non-Small-Cell Lung (U.S.) MK-6482 Welireg Von Hippel-Lindau (VHL) Disease (EU) Cough MK-7264 (gefapixant) (U.S.) (9) Pneumococcal Vaccine Adult V116 Capvaxive (EU) Pulmonary Arterial Hypertension MK-7962 Winrevair (EU) Certain Supplemental Filings Cancer MK-3475 Keytruda \u2022    First-Line Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (KEYNOTE-483) (U.S.) (EU) (JPN) \u2022    Primary Advanced or Recurrent Endometrial Carcinoma (KEYNOTE-868) (EU) (JPN) \u2022    First-Line Locally Advanced or Metastatic Urothelial Carcinoma (KEYNOTE-A39) (EU) (JPN) \u2022    High-Risk Locally Advanced Cervical Cancer (KEYNOTE-A18) (EU) (JPN) \u2022    Resectable Stage II, IIIA or IIIB (T3-4N2) NSCLC (KEYNOTE-671) (JPN) MK-6482 Welireg \u2022    Previously Treated Advanced Renal Cell Carcinoma (LITESPARK-005) (EU) (JPN) Footnotes: (1) Being developed in a collaboration. The change was primarily due to lower proceeds from the - 43 - issuance of debt, no proceeds from short-term borrowings and higher dividends paid to shareholders, partially offset by lower payments on long-term debt, lower purchases of treasury stock and higher p\nItem 7A. \u2014 1,192 Deferred income taxes ( 232 ) ( 632 ) Share-based compensation 379 314 Other 174 5 Net changes in assets and liabilities ( 4,394 ) ( 4,526 ) Net Cash Provided by Operating Activities 8,727 5,043 Cash Flows from Investing Activities Capital expenditures ( 1,652 ) ( 1,972 ) Purchases of securities and other investments ( 64 ) ( 587 ) Proceeds from sales of securities and other investments 320 785 Acquisition of Harpoon Therapeutics, Inc., net of cash acquired ( 746 ) \u2014 Acquisition of Prometheus Biosciences, Inc., net of cash acquired \u2014 ( 10,705 ) Acquisition of Imago BioSciences, Inc., net of cash acquired \u2014 ( 1,327 ) Other ( 303 ) 4 Net Cash Used in Investing Activities ( 2,445 ) ( 13,802 ) Cash Flows from Financing Activities Net change in short-term borrowings \u2014 1,937 Proceeds from issuance of debt 3,600 5,946 Payments on debt ( 751 ) ( 1,751 ) Dividends paid to stockholders ( 3,936 ) ( 3,738 ) Purchases of treasury stock ( 373 ) ( 487 ) Proceeds from exercise of stock options 160 112 Other ( 298 ) ( 315 ) Net Cash (Used in) Provided by Financing Activities ( 1,598 ) 1,704 Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash ( 220 ) ( 6 ) Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash 4,464 ( 7,061 ) Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $ 68 and $ 79 at January 1, 2024 and 2023, respectively, included in Other current assets ) 6,909 12,773 Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $ 69 and $ 52 at June\u00a030, 2024 and 2023, respectively, included in Other current assets ) $ 11,373 $ 5,712 The accompanying notes are an integral part of this condensed consolidated financial statement. Forward-looking snippets: Recently Adopted Accounting Standard In August 2023, the Financial Accounting Standards Board (FASB) issued amended guidance that requires a newly formed joint venture to recognize and initially measure its assets and liabilities at fair value upon formation. The amended guidance includes exceptions to fair value measurement that are consistent with the accounting for \nenerally accepted in the United States (U.S.) for complete consolidated financial statements are not included herein. Recently Adopted Accounting Standard In August 2023, the Financial Accounting Standards Board (FASB) issued amended guidance that requires a newly formed joint venture to recognize and initially measure its assets and liabilities at fair value upon formation. The amended guidance includes exceptions to fair value measurement that are consistent with the accounting for business combinations guidance. The amended guidance is effective prospectively for all joint ventures with a formation date on or after January 1, 2025, however existing joint ventures have the option to apply the guidance retrospectively."
}